The primary goal of this training program is to provide postdoctoral training in cancer biology for highly qualified individuals who wish to pursue an academic career in cancer research. The training faculty have expertise in many areas of cancer research including signal transduction, gene regulation, molecular biology of oncogenes and tumor suppressor genes, carcinogenesis, cancer therapeutics, cancer immunology, and viral oncology. Trainees will be selected based on their potential for a productive research career in cancer biology and will be supported for two years. In addition to the research experience in the laboratory of a faculty mentor, the training program has unique features that have been designed to enhance the education of trainees in many aspects of cancer biology. Trainees will be required to attend lectures in the cancer biology course, this course will include a clinical experience segment designed specifically for the trainees. Additionally, trainees will attend a seminar series in cancer biology, a journal club in cancer signal transduction, and will participate in a research forum specifically tailored to postdoctoral students. Trainees will also attend a meeting of the American Association for Cancer Research and will be encouraged to attend other meetings that focus on cancer research. Programs for the recruitment of minority trainees and formal instruction in the principles of scientific conduct and practice are in place in the training program. ? ?
| Landais, Igor; Sobeck, Alexandra; Stone, Stacie et al. (2009) A novel cell-free screen identifies a potent inhibitor of the Fanconi anemia pathway. Int J Cancer 124:783-92 |
| Landais, Igor; Hiddingh, Sanne; McCarroll, Matthew et al. (2009) Monoketone analogs of curcumin, a new class of Fanconi anemia pathway inhibitors. Mol Cancer 8:133 |
| Sobeck, Alexandra; Stone, Stacie; Landais, Igor et al. (2009) The Fanconi anemia protein FANCM is controlled by FANCD2 and the ATR/ATM pathways. J Biol Chem 284:25560-8 |
| Weinberg, Andrew D; Thalhofer, Colin; Morris, Nick et al. (2006) Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study. J Immunother 29:575-85 |
| Schittenhelm, M M; Yee, K W H; Tyner, J W et al. (2006) FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia 20:2008-14 |
